MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Echo Therapeutics, Inc. (ECTE) Is “One To Watch” 0 comments
    Sep 26, 2012 6:02 PM | about stocks: ECTE

    Echo Therapeutics is a transdermal medical device company with extensive expertise in advanced skin permeation technology. In particular, the company is developing the PreludeTM SkinPrep System to allow for painless and significantly enhanced skin permeation that will enable both needle-free drug delivery and analyte extraction, plus the Symphony tCGM System, a non-invasive, wireless, transdermal continuous glucose monitoring system for use in hospital critical care units and for people with diabetes.

    The skin permeation technology utilized is based upon Echo's patented feedback control algorithm, which allows system removal of only the outermost layer of dry dead skin cells, painlessly preparing the skin for optimal permeation. The whole process is designed as a safe, effective, fast-acting, and pain free platform for needle-free drug delivery as well as for the pain-free extraction of analytes used for things like glucose monitoring.

    The ability to painlessly monitor glucose levels will allow Echo to tap into the huge and growing global diabetes market. The cost of diabetes care in the U.S. alone is, according to the ADA, more than $174 billion, based upon a 2007 figure, including medical expenditures and lost productivity. The ADA estimates that people with diabetes average medical expenditures more than twice as high as those without diabetes, and that nearly 10% of all healthcare dollars can be attributed to the disease. In addition, a significant portion of overall diabetes care costs go to blood glucose monitoring.

    Echo currently has two key strategic partnerships in place:

    • Ferndale Pharma Group, Inc. and its wholly owned subsidiary Eloquest Healthcare Inc. have been licensed by Echo to develop, market, and sell the Prelude device for enhanced, fast acting, and needle-free delivery of Ferndale's topical lidocaine product in North America and the U.K.

    • Handok Pharmaceuticals Co., Ltd. has been licensed to develop, market, and sell the Symphony® tCGM System for continuous glucose monitoring in South Korea.

    For additional information, visit the company's website at www.EchoTX.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: ECTE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.